Essential thrombocytosis transformed AML with TP53 mutations and its clinical implications

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Essential thrombocytosis (ET) is a chronic myeloproliferative neoplasm.
• Transformation of ET to acute myeloid leukemia (AML) is a rare but serious complication.
• TP53 mutations are established risk factors for AML, but their role in ET transformation is under-researched.

Purpose of the Study:

• To investigate the clinical presentation and outcomes of ET patients who transform into AML.
• To analyze the impact of TP53 mutations on disease progression and treatment response in ET-transformed AML.
• To compare the therapeutic efficacy of decitabine in ET-transformed AML with and without TP53 mutations.

Main Methods:

• Case study analysis of three ET patients who transformed to AML.
• TP53 mutation status assessment.
• Evaluation of AML cell burden and patient survival.
• Assessment of response to decitabine treatment.

Main Results:

• Two of three ET-transformed AML patients had TP53 mutations and a higher AML cell burden.
• Patients with TP53 mutations exhibited shorter survival times with decitabine treatment.
• The ET-transformed AML patient without TP53 mutations showed a better response and longer survival (>20 months) to decitabine.

Conclusions:

• TP53 mutations in ET-transformed AML are associated with more aggressive disease and poorer outcomes with decitabine.
• The allelic burden of TP53 mutations may influence disease severity and treatment response.
• Further research with larger cohorts is necessary to understand the molecular mechanisms and optimize treatment strategies.